New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JBL;ARRS;GOOG;NYX;ICE;SD;ACN;BBBY;FOLD;GSK;MDRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
January 26, 2015
12:56 EDTGOOGGoogle shares should be bought ahead of earnings, says BGC Financial
BGC Financial analyst Colin Gillis expects Google (GOOG, GOOGL) to report Q4 Paid Click growth of 17% and a Cost Per Click decline of 2%, resulting in revenue of $18.9B and adjusted EPS of $7.22, both of which are above the consensus forecasts. Gillis recommends investors buy Google shares ahead of Thursday's earnings report and maintains a Buy rating and $650 price target on the stock.
11:41 EDTMDRXLeerink healthcare technology analyst holds analyst/industry conference call
Subscribe for More Information
11:39 EDTICENYSE, NASDAQ plan to keep normal hours today, tomorrow, Bloomberg says
Subscribe for More Information
10:51 EDTGOOGNFL highlights content coming to YouTube, Google Search results
Earlier today, The National Football League and YouTube announced a partnership that will deliver NFL content to fans around the world, combining the world’s most popular sports league with the world’s largest video platform. Through a newly launched official NFL channel on YouTube, and video directly viewable for Google Search users, this partnership will enable fans to engage with NFL video content on PCs, tablets, and mobile phones. This deal represents the latest in a series of partnerships that the NFL has struck with leading digital platforms to continue to increase the accessibility and consumption of some of the most "valuable" content in the entertainment business. Reference Link
10:00 EDTBBBYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Axle (AXL) upgraded to Overweight from Neutral at JPMorgan... Bed Bath & Beyond (BBBY) upgraded to Outperform from Perform at Oppenheimer... DRDGOLD (DRD) upgraded to Neutral from Underweight at JPMorgan... DealerTrack (TRAK) upgraded to Buy from Hold at Stifel... DreamWorks Animation (DWA) upgraded to Buy from Neutral at B. Riley... First Niagara (FNFG) upgraded to Buy from Hold at Jefferies... Fortinet (FTNT) upgraded to Buy from Neutral at Citigroup... Garmin (GRMN) upgraded at RBC Capital... Harmony Gold (HMY) upgraded to Overweight from Neutral at JPMorgan... Invesco (IVZ) upgraded to Positive from Neutral at Susquehanna... Kansas City Southern (KSU) upgraded at Raymond James... McDonald's (MCD) upgraded to Overweight from Equal Weight at Stephens... Melco Crown (MPEL) upgraded to Buy from Hold at Union Gaming... Monro Muffler (MNRO) upgraded to Neutral from Reduce at SunTrust... Pier 1 Imports (PIR) upgraded to Outperform from Perform at Oppenheimer... Piper Jaffray (PJC) upgraded to Neutral from Underperform at Macquarie... Randgold (GOLD) upgraded to Overweight from Neutral at JPMorgan... Rockwell Collins (COL) upgraded to Buy from Hold at Argus... Telefonica (TEF) upgraded to Neutral from Underperform at BofA/Merrill... Triumph Group (TGI) upgraded at RBC Capital... Unilever (UL) upgraded to Buy from Underperform at BofA/Merrill... WWE (WWE) upgraded to Neutral from Underperform at Macquarie.
09:19 EDTGSKGlaxoSmithKline announces availability of two new products for asthma
Subscribe for More Information
07:43 EDTBBBYOppenheimer upgrades Bed Bath & Beyond, Pier 1 on better macro outlook
Subscribe for More Information
06:21 EDTGOOGGoogle's Ludwig comments on vulnerabilities in versions of Webkit
Subscribe for More Information
05:37 EDTBBBYBed Bath & Beyond upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
January 25, 2015
20:32 EDTGOOGTwitter still has problems, Barron's says
Subscribe for More Information
January 23, 2015
12:42 EDTGOOGGoogle January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
10:02 EDTARRSOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTGOOGActive equity options trading
Subscribe for More Information
09:25 EDTARRSARRIS downgraded at Raymond James
Subscribe for More Information
08:52 EDTGSKArray BioPharma to hold a conference call
Subscribe for More Information
08:10 EDTGSKArray agrees to acquire rights to encorafenib
Array BioPharma (ARRY) announced that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015. Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib. As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights. Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit. At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array's full time equivalent costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period. For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array's FTE costs in connection with completing the trials. Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib. Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction. In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.
08:07 EDTGOOGU.S. tech giants nervous about backlash in Europe, WSJ says
Subscribe for More Information
08:02 EDTARRSARRIS downgraded to Outperform from Strong Buy at Raymond James
Subscribe for More Information
07:44 EDTGSKGlaxo says now in position to deliver 'tens of thousands' of Ebola vaccine doses
Witty expects to start seeing data from trials of Ebola vaccines in next four to five months. GlaxoSmithKline CEO Andrew Witty speaking on CNBC.
06:39 EDTGSKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 22, 2015
19:40 EDTGOOGGoogle's entrance into telecommunications may not be beneficial, Re/code says
Subscribe for More Information
14:57 EDTGOOGRKG data read through for Google a positive, says Morgan Stanley
Subscribe for More Information
13:57 EDTGOOGGoogle initiated with a Buy at Societe Generale
Target $615.
10:29 EDTGOOGRumor: Twitter strength attributed to takeover speculation
Subscribe for More Information
09:43 EDTSDActive equity options trading
Active equity options trading according to Track Data: AAPL DG ABX AMZN FXCM LVS FFIV INFI SD
08:11 EDTGOOGGoogle January weekly volatility elevated into Q4 and capital allocation outlook
Google January weekly call option implied volatility is at 37, February is at 23, March is at 20; compared to its 26-week average of 23 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on January 29.
January 21, 2015
18:10 EDTGOOGGoogle, Viacom win dismissal of suit on children's web privacy, Re/code reports
Subscribe for More Information
16:28 EDTGOOGGoogle to launch phone service with Sprint, T-Mobile, The Information says
Google (GOOG, GOOGL) is expected to reach deals to buy wholesale access to Sprint (S) and T-Mobile’s (TMUS) voice and data networks in order to sell mobile phone plans directly to customers, according to The Information, citing three people with knowledge of the plans. Google, which may put itself into competition with carrier leaders Verizon (VZ) and AT&T (T) with the new service, "seems likely" to launch the offering this year, according to the report. Reference Link
12:30 EDTGSKGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
11:34 EDTGOOGAmazon pulling plug on Amazon Wallet app beta, CNet reports
Subscribe for More Information
08:07 EDTGOOGUSPTO Examiner reconfirms patentability of Netlist's LRDIMM patent claims
Netlist (NLST) announced that the Examiner in the consolidated reexamination of U.S. Pat. No. 7,619,912 issued an Answer maintaining the patentability of 92 claims related to LRDIMM. The reexaminations were brought in the United States Patent and Trademark Office by Google (GOOG), Inphi Corporation, and SMART Modular Technologies. The 92 patentable claims are generally directed to the fundamental concept of rank multiplication which is integral to the design of the LRDIMM. The Examiner issued the Answer on January 14, 2015, in response to voluminous appeal briefs filed by Google, Inphi, and SMART Modular. The Examiner considered arguments from all parties and ultimately maintained his conclusions as to the patentability of these claims, while maintaining the rejection of 11 other claims. The parties will now have the opportunity to file rebuttal briefs before the reexamination proceeds to the Patent Trial and Appeals Board for oral arguments, likely later this year or early next. The '912 Patent is also the subject of litigation between Netlist and Google in the Northern District of California and Netlist and Inphi in the Central District of California. Both sets of litigation have been stayed pending the outcome of this and other reexamination proceedings.
January 20, 2015
18:45 EDTGOOGSpaceX raises $1B, Google, Fidelity to own slightly under 10%, Bloomberg says
Elon Musk's Space Exploration Technologies Corp. has sold an approximately 10% stake to Google (GOOG) and Fidelity for $1B, Bloomberg reports. Reference Link
16:34 EDTGOOGSpacex has raised $1B, Google and Fidelity to own slightly under 10%
Subscribe for More Information
11:25 EDTGOOGGoogle partners with Cloudera to bring Cloud Dataflow to Spark
Subscribe for More Information
11:21 EDTGOOGYouTube plans launch of original content initiative by end of 2015, Variety says
Subscribe for More Information
09:06 EDTICENYSE completes minority investment in Coinbase
Subscribe for More Information
07:31 EDTSDSandRidge Energy upgraded to Hold from Reduce at KLR Group
Subscribe for More Information
07:00 EDTGOOGEU official calls on Google to make more concessions, NY Times says
Subscribe for More Information
January 19, 2015
17:57 EDTGOOGGoogle near $1B investment in SpaceX, WSJ reports
Google is near an agreement to invest $1B in Elon Musk's SpaceX, Wall Street Journal reports, citing a person familiar with the matter. The investment would value SpaceX at more than $10B, the Journal adds. The Information earlier today reported Google was near an investment in SpaceX, but did not specify the amount. Reference Link
12:29 EDTGOOGGoogle near investment in Musk's SpaceX, The Information reports
Subscribe for More Information
January 18, 2015
13:45 EDTGOOGGoogle in talks to acquire mobile-pay platform Softcard, WSJ says
Subscribe for More Information
January 16, 2015
09:09 EDTGOOGYouTube to host Super Bowl halftime show
YouTube will host a Halftime Show produced in collaboration with Collective Digital Studio that will be live streamed on the AdBlitz Channel, the Google (GOOG, GOOGL) property announced in a blog post. The show will feature more than 20 YouTube creators and musicians with over 60M combined subscribers, YouTube stated. The Super Bowl is being broadcast on Sunday, Feb. 1 on Comcast's (CMCSA) NBC Network. Reference Link
08:31 EDTGSKGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
07:33 EDTGOOGAlign Technology near-term risk/reward less favorable, says Credit Suisse
Subscribe for More Information
07:13 EDTICEIntercontinentalExchange February volatility elevated into Q4 and outlook
Subscribe for More Information
January 15, 2015
14:52 EDTGOOGGoogle investment Magic Leap files new patent, Business Insider says
The startup Magic Leap, which raised $542M in an October 2014 funding led by Google, filed a new patent that indicates a device that is "head worn component" and according to Business Insider "looks like an intense version of Google Glass that works with a belt pack." Business Insider added, "All we really know for sure so far is that Magic Leap is creating some sort of augmented reality — which it calls 'cinematic reality' — that the company believes will provide a more realistic 3D experience than anything else that's out there today." Reference Link
14:31 EDTGSKMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
13:06 EDTGOOGGoogle to stop selling Glass to individuals on January 19, WSJ reports
Subscribe for More Information
10:19 EDTBBBYOptions with decreasing implied volatility
Subscribe for More Information
09:08 EDTGOOGLendingClub and Google partner for new business financing program
Lending Club (LC) announced a new pilot program in partnership with Google (GOOG) to facilitate low-interest financing to eligible Google partners. The program allows Google to purchase the loans, thus investing its own capital in its partner network to drive business growth. Lending Club will service the loans.
09:05 EDTGOOGGoogle and PricewaterhouseCoopers partner to bid for DoD healthcare program
Subscribe for More Information
08:36 EDTGSKOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
07:20 EDTICENASDAQ may enter energy derivatives market, Reuters reports
Subscribe for More Information
06:30 EDTGOOGGoogle in talks with major automakers on driverless cars, Reuters reports
Google (GOOG) is in talks with many of the top automakers in the world, including Toyota (TM), GM (GM) and Ford (F), about developing driveless vehicles, the director of Google's self-driving car project said yesterday, according to Reuters. The tech giant has also hired a group of "traditional and nontraditional suppliers" to bolster its efforts, with Nvidia (NVDA) one of the latter group, the news service quoted the executive as saying. Google aims to bring driverless vehicles to the market by 2020, the executive said, Reuters reported. Reference Link
06:09 EDTFOLDAmicus Therapeutics promotes Bradley Campbell to President and COO
Subscribe for More Information
January 14, 2015
12:21 EDTGOOGGoogle to launch smartphone in test market of Puerto Rico, Tech Crunch says
Subscribe for More Information
10:27 EDTGOOGFacebook, Google seen at front of 'multi-year' positive run for Internet stocks
Subscribe for More Information
10:21 EDTBBBYOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTSDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ACE Limited (ACE) downgraded to Neutral from Outperform at Macquarie... AXIS Capital (AXS) downgraded to Neutral from Outperform at Macquarie... Allstate (ALL) downgraded to Underperform from Neutral at Macquarie... Altera (ALTR) downgraded to Neutral from Overweight at JPMorgan... American Midstream Partners (AMID) downgraded to Neutral from Buy at BofA/Merrill... Argo Group (AGII) downgraded to Underperform from Neutral at Macquarie... Aspen Insurance (AHL) downgraded to Underperform from Neutral at Macquarie... Beneficial Bancorp (BNCL) downgraded to Neutral at Boenning & Scattergood... CDW Corporation (CDW) downgraded to Neutral from Buy at Goldman... CHC Group (HELI) downgraded at Raymond James... CIRCOR (CIR) downgraded to Hold from Buy at Stifel... Chesapeake (CHK) downgraded to Underweight from Equal Weight at Barclays... Commerzbank (CRZBY) downgraded to Sell from Neutral at Goldman... Continental Resources (CLR) downgraded to Equal Weight from Overweight at Barclays... Corporate Office Properties (OFC) downgraded to Market Perform at Wells Fargo... Credit Suisse (CS) downgraded to Neutral from Overweight at HSBC... Datawatch (DWCH) downgraded to Hold at Canaccord... Devon Energy (DVN) downgraded to Equal Weight from Overweight at Barclays... Dollar Tree (DLTR) downgraded to Neutral from Buy at Northcoast... Douglas Emmett (DEI) downgraded to Neutral from Buy at Mizuho... Dresser-Rand (DRC) downgraded to Underperform from Market Perform at Raymond James... Enable Midstream (ENBL) downgraded to Underperform from Neutral at BofA/Merrill... F5 Networks (FFIV) downgraded to Equal Weight from Overweight at Barclays... First Majestic (AG) downgraded to Sector Perform from Outperform at Scotia Capital... Foot Locker (FL) downgraded to Sell from Neutral at Goldman... Franklin Resources (BEN) downgraded to Neutral from Buy at Goldman... HCP (HCP) downgraded to Market Perform from Outperform at Wells Fargo... Halcon Resources (HK) downgraded to Underweight from Equal Weight at Barclays... Insulet (PODD) downgraded at Sterne Agee... J.B. Hunt (JBHT) downgraded to Market Perform from Outperform at Avondale... JPMorgan (JPM) downgraded to Underweight from Neutral at HSBC... KB Home (KBH) downgraded to Neutral from Outperform at Credit Suisse... Kosmos (KOS) downgraded to Equal Weight from Overweight at Barclays... Marathon Oil (MRO) downgraded to Equal Weight from Overweight at Barclays... Medley Management (MDLY) downgraded to Market Perform at Keefe Bruyette... MoneyGram (MGI) downgraded to Underperform from Neutral at BofA/Merrill... NPS Pharmaceuticals (NPSP) downgraded to Neutral from Overweight at JPMorgan... National Grid (NGG) downgraded to Underperform from Neutral at Credit Suisse... Navigators (NAVG) downgraded to Underperform from Neutral at Macquarie... Pioneer Energy (PES) downgraded at Raymond James... RSP Permian (RSPP) downgraded to Equal Weight from Overweight at Barclays... Rambus (RMBS) downgraded to Neutral from Overweight at JPMorgan... Realty Income (O) downgraded to Market Perform from Outperform at Wells Fargo... Red Hat (RHT) downgraded to Sell from Neutral at Goldman... Resolute Energy (REN) downgraded to Underweight from Equal Weight at Barclays... Ross Stores (ROST) downgraded to Neutral at UBS... SandRidge Energy (SD) downgraded to Underweight from Equal Weight at Barclays... Tech Data (TECD) downgraded to Sell from Neutral at Goldman... Teekay Offshore Partners (TOO) downgraded to Neutral from Buy at BofA/Merrill... Travelers (TRV) downgraded to Underperform from Neutral at Macquarie... TrueCar (TRUE) downgraded to Market Perform at Cowen... Valspar (VAL) downgraded to Neutral from Outperform at RW Baird... Verizon (VZ) downgraded at Evercore ISI... Viacom (VIAB) downgraded to Sell from Buy at Citigroup... W. R. Berkley (WRB) downgraded to Underperform from Neutral at Macquarie... Waddell & Reed (WDR) downgraded to Neutral from Buy at Goldman... Western Union (WU) downgraded to Underperform from Neutral at BofA/Merrill... Whiting Petroleum (WLL) downgraded to Equal Weight from Overweight at Barclays... Whole Foods (WFM) downgraded to Hold from Buy at Argus... Xilinx (XLNX) downgraded to Neutral from Overweight at JPMorgan... iRobot (IRBT) downgraded to Underweight from Neutral at JPMorgan.
09:46 EDTGOOGGoogle initiated with a Buy at Rosenblatt
Target $575.
09:36 EDTGOOGActive equity options trading
Subscribe for More Information
08:15 EDTGOOGGoogle sentiment may be overly negative, says RW Baird
Baird believes investor sentiment for Google may be overly negative, exacerbated by the accelerating shift to mobile. The firm believes that 50%-60% of Google's revenues are already coming from Mobile, Video, Local Enterprise and other segments, which removes worries about desktop dependence. Baird also noted the company's valuation is at the low end of comparable multiples, suggesting a favorable risk/reward scenario. Baird reiterated its Outperform rating and $680 price target on Google shares.
07:41 EDTGOOGGoogle risk/reward compelling, says SunTrust
Subscribe for More Information
07:41 EDTSDGlobal Hunter Securities to hold a conference
Subscribe for More Information
07:37 EDTMDRXJPMorgan to hold a conference
Subscribe for More Information
06:29 EDTGOOGCompanies reach new deal on worker hiring issue, Reuters says
Subscribe for More Information
06:14 EDTGOOGMediaTek: Worldwide tablet shipments rise at slower pace, DigiTimes says
Subscribe for More Information
06:14 EDTSDSandRidge Energy downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded SandRidge Energy to Underweight and other names in the Exploration & Production space saying downside risk outweighs potential gains, even if oil prices recover. The firm reduced its commodity price deck assumptions and believes investor expectations for an oil price recovery could prove disappointing. It lowered its price target for shares to 50c from $1.50.
January 13, 2015
13:56 EDTGOOGGM open to partnering with Google on self-driving cars, Time says
GM (GM) would be open to having a discussion with Google (GOOG) about jointly developing self-driving cars, GM Chief Technology Officer Jon Lauckner said, according to Time Magazine. Reference Link
12:32 EDTGOOGGoogle February volatility elevated as shares rally from 14-month low
Google January call option implied volatility is at 21, January weekly is at 22, February is at 28, March is at 23; compared to its 26-week average of 22 according to Track Data, suggesting large near tem price movement.
10:17 EDTBBBYOptions with decreasing implied volatility
Subscribe for More Information
09:36 EDTGOOGActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
January 12, 2015
13:14 EDTGOOGAnalysts take opposite sides in regards to Google shares
Subscribe for More Information
12:04 EDTGSKNovartis sees closing GSK transactions in 1H15
Novartis (NVS) says portfolio transformation is progressing "on track." Sees closing GlaxoSmithKline (GSK) transactions in 1H. In 2015, plans to execute integration of GSK oncology business, execute separation of Vaccines, ensure successful start-up of Consumer Health JV with GSK. Sees NBS to continue to deliver synergies. Comments from slides that are being presented at the JP Morgan Healthcare Conference.
11:19 EDTGOOGGoogle set to provide real-time translation via Translate app, NY Times reports
Subscribe for More Information
10:15 EDTBBBYOptions with decreasing implied volatility
Options with decreasing implied volatility: NBIX APOL NPSP BBBY INFY JCP MU TIF
10:00 EDTGOOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:40 EDTGOOGGoogle no longer fixing older Android security flaws, WSJ reports
Subscribe for More Information
09:22 EDTGOOG23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
08:37 EDTGSKShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:21 EDTGOOGApple poised to gain market share, says JMP Securities
Subscribe for More Information
08:02 EDTGOOGGoogle shares undervalued, says Bernstein
Subscribe for More Information
07:49 EDTFOLDAmicus Therapeutics sees current cash to fund operations into 2017
Amicus Therapeutics provided its full-year 2015 strategic outlook and financial guidance. The company sees its FY15 net cash spend expected to range between $73M-$83M. Current cash of $169.1M at December 31, 2014 is projected to fund operating plan into 2017. Amicus said migalastat monotherapy FDA interaction is planned in 1Q15 and an MAA submission is on track for mid-2015 to seek marketing approval for Fabry patients with amenable mutations. Initiation of longer-term Phase 2 Fabry co-administration study is anticipated in 2015 in support of Fabry franchise strategy to develop migalastat in combination with ERT for Fabry patients with non-amenable mutations. Next-generation Pompe ERT is set to enter clinic in 2H15 and additional details on Pompe program are to be highlighted at 33rd Annual J.P. Morgan Healthcare Conference, the company said.
07:38 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
06:46 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
06:22 EDTGSKWHO approves 2 ebola vaccines to enter West Africa trials, Financial Times says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use